Two greater finish fashions of the Apple Watch can go on sale once more after a federal court docket quickly lifted a gross sales halt ordered by the Worldwide Commerce Fee over a patent dispute.

The ITC, a federal company, ordered the halt in October to dam Apple from utilizing particular applied sciences underpinning a blood-oxygen measurement system in its Collection 9 and Extremely 2 watches. That halt to gross sales started amid an mental property dispute between Apple and the medical expertise firm Masimo.

Apple reduce off on-line gross sales of the watches within the U.S. on final week simply days from the Christmas vacation to adjust to the ITC ruling. The court docket’s motion will enable gross sales of the 2 Apple Watch fashions whereas it considers whether or not to proceed permitting gross sales whereas it hears Apple’s attraction. As of three p.m. Japanese Time on Wednesday, neither of the Apple Watch fashions in query had been obtainable at Apple‘s on-line retailer.

This isn’t the primary patent roadblock the Apple Watch has run into as the corporate morphs its watches into health-management gadgets. Final yr, the ITC dominated that Apple had infringed on the wearable EKG expertise of AliveCor – a call the Biden administration declined to overturn. That dispute hasn’t instantly affected Apple Watch gross sales but as a result of one other regulatory physique had dominated that AliveCor’s expertise isn’t patentable. The authorized tussle on that challenge continues to be ongoing.

The patent complications dealing with Apple because it tries to infuse extra medical expertise into its watch fashions makes it more and more probably the corporate will both have to start out figuring out licensing offers or just buying startups specializing within the subject, Wedbush Securities analyst Dan Ives predicted.